Study to Evaluate Tezepelumab in Adults with Severe Uncontrolled Asthma - DIRECTION

Study identifier:D5180C00021

ClinicalTrials.gov identifier:NCT03927157

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

405

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 14 Jun 2019
Estimated Primary Completion Date: 29 May 2024
Estimated Study Completion Date: 19 Aug 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Amgen

Inclusion and exclusion criteria